Maynard, Mass., March 18, 2013—Allegro Diagnostics today announced its participation in the Oncology Biomarkers Conference, part of GTC’s Biomarker Summit 2013 being held March 20-22, 2013 in San Francisco. Duncan Whitney, Ph.D., Senior Vice President, Research, Development and Technical Operations, is presenting the talk “Improving the Diagnostic Yield of Bronchoscopy for Lung Cancer Using Bronchial Airway Gene-expression Testing” on Thursday, March 21 at 4:10 p.m. Dr. Whitney will discuss up and down regulated genes associated with smoking damage, Allegro’s lead genomic test, BronchoGen™, and the AEGIS clinical trials.
About the AEGIS Clinical Trials
The Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer (AEGIS) trials are prospective, case-controlled, multi-center studies designed to evaluate the prediction accuracy of the BronchoGen™ genomic test compared to bronchoscopy alone and in combination with bronchoscopy. The AEGIS trials have included 25 medical centers throughout the United States with 730 patients enrolled in AEGIS I and over 1300 enrolled in AEGIS II. All patients have been current or former smokers undergoing bronchoscopy for suspicion of lung cancer. Endpoints include the sensitivity, specificity and negative predictive value of BronchoGen for identifying patients with malignancy. The AEGIS II trial completed patient enrollment in July 2012 with final results expected in Q3 2013.
MacDougall Biomedical Communications
Charles Liles MacDougall Biomedical Communicaticliles@macbiocom.com